Showing 391-400 of 7665 results for "".
- Survey: Gen Z and Millennial Men Fall Short on Face Washing, Skin Carehttps://practicaldermatology.com/news/survey-gen-z-and-millennial-men-fall-short-on-face-washing-skin-care/2461656/Many Gen Z and millennial men would rather going on a bad date than take care of their skin, according to a new survey conducted by OnePoll on behalf of CeraVe. In a recent survey of 2,000 men ages 18–26 and 27–42, two in five (42%) revealed they need someone to confront them about their skin care…
- Prior Immunotherapy May Predict Response to PD-1 Checkpoint Blockadehttps://practicaldermatology.com/news/prior-immunotherapy-may-predict-response-to-pd-1-checkpoint-blockade/2461655/Responses to PD-1 checkpoint blockade in patients with advanced melanoma depend on whether or not they had previously received CTLA-4 blockade as well as other factors, new research suggests. Their findings, based on analysis of seven data sets generated over the past decade, which included result…
- ASA Honors Dr. Mark G. Lebwohl, Leo Pharmahttps://practicaldermatology.com/news/asa-honors-dr-mark-g-lebwohl-leo-pharma/2461652/Mark G. Lebwohl, MD and LEO Pharma received honors at the American Skin Association’s (ASA) annual Spring Gala, "We were proud to honor Dr. Mark Lebwohl and LEO Pharma for their dedication to the field of dermatology. Both honorees share in ASA's crucial mission of finding cures for skin disease…
- Millennials, Gen Xers Not Well-Schooled on Skin Cancer Preventionhttps://practicaldermatology.com/news/millennials-gen-xers-not-well-schooled-on-skin-cancer-prevention/2461648/Millennials and Gen Xers are racked with sun regrets, a new survey shows. Just 19% of millennials and Gen Xers wear sunscreen all year, 35% used a tanning bed, and 46% regretted how long they stayed out in the sun when they were younger. This is why DermTech, Inc. is now developing a direct-to-c…
- The American Acne and Rosacea Society Offers #RosaceaRescues During Rosacea Awareness Monthhttps://practicaldermatology.com/news/the-american-acne-and-rosacea-society-offers-rosacearescues-during-rosacea-awareness-month/2461647/In recognition of National Rosacea Awareness Month in April, experts from the American Acne and Rosacea Society (AARS) are working to educate the public about the disease, its impact, and its treatment. Throughout the month, they are sharing #RosaceaRescues—science-backed, medically-based strategie…
- Xylyx Bio's Matrikynes Improves the Structure, Function, and Appearance of Skinhttps://practicaldermatology.com/news/xylyx-bios-matrikynes-improves-the-structure-function-and-appearance-of-skin/2461645/Xylyx Bio’s proprietary Matrikynes ingredient is safe and highly effective for anti-aging and other topical skin applications, a new study shows. Matrikynes is comprised of a proprietary mixture of natural extracellular matrix-derived peptides called matrikines. The intrinsic bioactivity of matrik…
- Mount Sinai Wins $1.3M Grant to Expand Skin Biology Research Training Programhttps://practicaldermatology.com/news/mount-sinai-wins-13m-grant-to-expand-skin-biology-research-training-program/2461643/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai will expand its research training program in skin biology with support from a five-year, $1.3 million T32 grant from the National Institutes of Health (NIH) and the National Institute of Arthri…
- It's Official: April Is the Coolest Month of the Yearhttps://practicaldermatology.com/news/its-official-april-is-the-coolest-month-of-the-year/2461642/April 2023 marks the first-ever CoolMonth, according to Allergan Aesthetics, an AbbVie company and the parent company of CoolSculpting Elite. Why April? A survey revealed 85% of people have a season in which they begin to think more about getting rid of stubborn body fat, and for 40% of those pe…
- Phase 3 Data Evaluating Almirall’s Lebrikizumab in Moderate-to-Severe Atopic Dermatitis Publishedhttps://practicaldermatology.com/news/phase-3-data-evaluating-almiralls-lebrikizumab-in-moderate-to-severe-atopic-dermatitis-published/2461640/Almirall announced the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two identical 52-week randomized, double-blind, placebo-controlled, para…
- Bristol Myers Squibb Receives European Commission Approval of Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/bristol-myers-squibb-receives-european-commission-approval-of-sotyktu-for-plaque-psoriasis/2461634/The European Commission has approved Sotyktu (deucravacitinib; Bristol Myers Squibb), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The approval was based on results from…